An interventional study of Acceptance and Commitment Therapy in Acceptance and Commitment Therapy, Psychological Distress and Stress Urinary Incontinence in Women, sponsored by University of Lincoln. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Lincoln · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Patient Safety Commissioner estimates that at least 10,000 women in England have experienced significant harm resulting from vaginal mesh implants. Adverse effects resulting in psychological distress and reduced quality of life have been reported. The purpose of the study is to explore the efficacy of Acceptance and Commitment Therapy (ACT) for women with mesh injury experiencing psychological distress.
The study will use a Hermeneutic Single-Case Efficacy Design to answer the primary and secondary objectives.
Primary objective: To investigate whether ACT is an effective therapeutic intervention for women experiencing psychological distress due to mesh injury.
Secondary objectives: To determine whether there are any meaningful changes throughout the ACT intervention; whether these changes can be attributed to the ACT intervention and what factors contribute to the changes.
Participants will undergo a ten-session ACT intervention and follow-up session. A qualitative interview will be carried out to explore the change experience.
NICE guidelines recognise the physical and psychological impact of mesh complications and recommends that psychological and psychosexual support is offered to women affected. Despite this, a therapeutic intervention for mesh complications has not yet been explored. Acceptance and Commitment Therapy (ACT) as been empirically supported for its use with populations with long term health conditions.
The study will use a hermeneutic single-case efficacy design and evaluate the process of change during the intervention. Following the ACT intervention, rich case records for each participant will be created using quantitative and qualitative data; this data will consist of demographic data, outcome measures and therapy material. The rich case records will be cross-referenced and amalgamated into an "affirmative" brief that presents evidence that the change can be attributed to the therapeutic intervention. The rich case record will also be analysed for indirect evidence to develop a "skeptic" brief, a brief presenting an alternative explanation for the therapeutic change. Both analyses will be evaluated through a presentation of both briefs, a rebuttal of the opposing brief and a summary narrative . The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome.
522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.
This study's planned enrollment of 6 is below the median of 80 across 337 interventional studies indexed under Pelvic Organ Prolapse.
Browse Pelvic Organ Prolapse studies →University of Lincoln is the lead sponsor of 27 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Woman aged 18 or over.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a ten-session Acceptance and Commitment Therapy (ACT) intervention
Behavioral: Acceptance and Commitment Therapy
Acceptance and commitment therapy (ACT) is a "third wave" Cognitive Behavioural Therapy that focuses on increasing psychological flexibility and acceptance of difficult experiences by undertaking value-drive actions despite psychological suffering. Psychological flexibility is developed and expanded through six core processes: acceptance, defusion, present moment awareness, self-as-context, values and committed action. Adherence to a strict protocol is not mandated for an ACT intervention; the study will be informed by an adapted ACT intervention for chronic pain (Scott et al., 2018). The intervention will reflect the heterogenous nature of mesh injury. The intervention will consist of ten individual weekly sessions lasting up to 60 minutes.
Hermeneutic Single-Case Efficacy Design - adjudication
The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome (Elliott et al., 2009).
Time frame: Through study completion, an average of 9 months.
Psychological distress assessed using the Clinical Outcomes in Route Evaluation 10 (CORE-10; Barkham et al., 2013)
10-item measure designed to measure common presentations of psychological distress. The minimum value is 0 and the maximum value is 40. A higher score indicates severe distress.
Time frame: From baseline to the end of treatment, up to 16 weeks.
Mesh symptoms impact on quality of life assessed using the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol; Kelleher et al., 1997)
20-item measure designed to measure the physical, emotional, social, and practical impact of urinary symptoms. Measure adapted to assess "mesh problem" instead of "urinary problem" (Brown, 2020). The minimum value is 0 and the maximum value is 76. A higher score indicates greater impact on quality of life.
Time frame: From baseline to the end of treatment, up to 16 weeks.
Psychological flexibility assessed using the Comprehensive assessment of Acceptance and Commitment Therapy Processes (CompACT-10; Golijani-Moghaddam et al., 2023)
10-item short-form version of the Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT), designed to measure psychological flexibility and its core sub-processes. The minimum value is 0 and the maximum value is 60. A higher score indicates greater level of psychological flexibility.
Time frame: From baseline to the end of treatment, up to 16 weeks.
Therapeutic alliance assessed using the Session Rating Scale (SRS; Duncan et al., 2003)
4-item measure designed to measure the quality of the therapeutic alliance. The minimum value is 0 and the maximum value is 40. A higher score indicates greater therapeutic alliance.
Time frame: Weekly during the therapy intervention, up to 10 weeks.
Client's perception of therapy sessions assessed using the Helpful Aspects of Therapy (HAT; Llewelyn, 1988)
A measure designed to identify specific events that participants found most helpful during the therapy session. The minimum value is 1 and the maximum value is 9 for each scale. A higher score indicates greater helpful impact.
Time frame: Weekly during the therapy intervention, up to 10 weeks.
Change in client's goals assessed using the Personal Questionnaire (PQ; Elliott et al., 1999)
A measure personalised to the participant, identifying problems that the participant would like to work on in therapy. The minimum value is 7 and the maximum value is 91 for each scale. A higher score indicates greater progress towards goals/problem identified at the start of therapy.
Time frame: Weekly during the therapy intervention, up to 10 weeks.
Adherence to ACT processes measured using the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM; O'Neill et al., 2019)
A measure of therapist fidelity in delivering Acceptance and Commitment Therapy. The minimum value is 0 and the maximum value is 36 for ACT consistent and ACT inconsistent subscales. A higher score for the ACT consistent subscale indicates adherence to ACT processes.
Time frame: During the therapy intervention for up to 10 weeks.
Client's perception of therapy intervention and change processes assessed using the Client Change Interview (Elliott et al., 2001)
A semi-structured interview to explore the mechanism of change.
Time frame: Within two weeks of end of therapy intervention, at 12 weeks.
No study locations are listed for this record.
Plan to share: No — The results of the research study will be submitted in partial fulfilment of doctoral thesis in Clinical Psychology. A journal manuscript will be submitted to a peer-reviewed journal and any data submitted will be anonymised. Any published outputs will contain a data availability statement linked to the repository. The full dataset and any special category data will not be publicly available due to participant privacy.
Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.
Of 162 non-industry interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 8 months is below that.
Counting every sponsor, half of 179 studies reached it within 23 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Lincoln